let's stick with the facts
Bavi has never had an unequivocally successful trial phase I II or otherwise. It is safe but so is a sugar pill. There are only promising, exciting, showing trend, leaning towards type data.
Upper management has zero experience exiting. You can find biotech veterans with serial successes developing and selling companies. You cannot find one of those at PPHM
Bavi started as an anti-angiogenic now it has morphed into an immunotherapy. Every conference call brings the idea of exciting possibilities. How about a conference call that provides direction and shows PPHM consistently sticking to that script instead of making it up as they go along. One CC, emphasize Cotara, next Bavi in pancreatic cancer, then Bavi in breast cancer, then imaging, then Avid then lather rinse and repeat. Then bring in Brekken,
Getting the word out is not what a company with a real pharmaceutical does or has to do. BP does not sit around and say we have to suppress Bavi cause it will put us out of business.
BP does say, oh yeah, I heard of that company, they screwed up their trial. Not sure how an antibody to a structural phospholipid would work. The antibody isn't even to the lipid is it. It's to beta-glycoprotein. Interesting, think I'll pass on it. ( they are usually polite).
The company does spend a lot of money on upper management, conferences and symposia. This money would be much better spent on science, upgrading equipment, hiring scientific talent etc.
Bavi is years away from approval and they don't have the money to get there, especially when a sizeable amount of the ATM goes to paying SK and his friends.
Market Data 
Markets 
AI
